Disease · EFO_0004952

disease recurrence

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. disease recurrence. Diseases, record EFO_0004952. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004952

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: disease recurrence
Open Targets ID: EFO_0004952
Other names: relapse
Highest stage of its drugs: Phase 3, for 4 of its 44 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PEGINTERFERON ALFA-2B	CHEMBL1201561	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RIBAVIRIN	CHEMBL1643	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
FLOXURIDINE	CHEMBL917	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DASATINIB ANHYDROUS	CHEMBL1421	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets68

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Bcr/Abl fusion protein	4	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	4	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	2	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor; Inosine-5'-monophosphate dehydrogenase 1 inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	2	Platelet-derived growth factor receptor beta inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/10714	Drugs and targets

1 to 10 of 68

See all 68 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00281879	Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer	Phase 2	200	2012-06-19	Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood	BUSULFAN, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOSPORINE, CYTARABINE, ETOPOSIDE, FILGRASTIM, FLUDARABINE PHOSPHATE, MELPHALAN, METHOTREXATE, METHYLPREDNISOLONE, TACROLIMUS ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT00218387	Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1	Phase 2	123	2019-04-10	Cocaine Dependence	MODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT03872388	Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy	Phase 2	6	2024-10-02	Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT03154827	Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)	Phase 1/2	1	2024-09-05	Acute Myeloid Leukemia	ATEZOLIZUMAB, MOTIXAFORTIDE	Its record names the disease	ClinicalTrials.gov
NCT04660344	A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy	Phase 3	761		Muscle-invasive Bladder Cancer	ATEZOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01207310	Pager-Assisted Smoking Cessation Treatment	Not applicable	224		Smoking Cessation	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT06477549	BeFluBu vs FluBuRux Conditioning in Haploidentical HCT	Phase 2	220		Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes	BENDAMUSTINE HYDROCHLORIDE, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT07254793	Prophylactic DLI-X for Leukemia Relapse After HCT	Phase 1	180		Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma	BLINATUMOMAB	Its record names the disease	ClinicalTrials.gov
NCT05850546	Rituximab in the First Episode of Paediatric Nephrotic Syndrome	Phase 3	138		Steroid-Sensitive Nephrotic Syndrome	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT06734585	Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant		114		Acute Myeloid Leukemia	GILTERITINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38165016	RESULT	1	PubMed
36223961	RESULT	2	PubMed
41406937	DERIVED	1	PubMed
41124204	DERIVED	1	PubMed
37082935	DERIVED	1	PubMed
30081865	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0004952

GET https://conductscience.org/api/diseases/v1/EFO_0004952/drugs?page=2

API reference For AI assistants